Phase II study of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of bronchogenic carcinoma.
D000477:Alkylating Agents / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009603:Nitroso Compounds / Q000627:therapeutic use*; D013997:Time Factors; D014508:Urea / Q000627:therapeutic use*
D000477:Alkylating Agents; D009603:Nitroso Compounds; D014508:Urea; D002330:Carmustine